AtaiBeckley Inc. 4

Chief Accounting Officer Anne Nagengast Johnson had approximately 3.13 million AtaiBeckley equity-based awards (stock options and RSUs) cancelled and cashed out at the $6.75 per share merger price plus CVRs in connection with the Eli Lilly acquisition, leaving her with no remaining AtaiBeckley shareholdings.

On September 11, 2026, in connection with the closing of the Eli Lilly acquisition of AtaiBeckley Inc., Chief Accounting Officer Anne Nagengast Johnson had all of her equity awards cancelled and cashed out: 3,015,996 shares underlying vested and unvested stock options with exercise prices ranging from $1.18 to $5.68 per share were converted into cash equal to the in‑the‑money value based on the $6.75 per share merger price plus one contingent value right (CVR) per underlying share, and 117,000 restricted stock units were similarly cancelled for cash at $6.75 per share plus one CVR per unit. Following these merger-related conversions, the Form 4 reports zero shares of common stock or derivative securities owned directly, indicating that her prior positions in AtaiBeckley equity securities were effectively liquidated into cash and CVRs as part of the transaction.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036388

Alert Tier

6